0001209191-23-026527.txt : 20230502
0001209191-23-026527.hdr.sgml : 20230502
20230502163354
ACCESSION NUMBER: 0001209191-23-026527
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230430
FILED AS OF DATE: 20230502
DATE AS OF CHANGE: 20230502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wolff Stefani
CENTRAL INDEX KEY: 0001751790
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39398
FILM NUMBER: 23879678
MAIL ADDRESS:
STREET 1: C/O PRINCIPIA BIOPHARMA INC.
STREET 2: 400 EAST JAMIE COURT, SUITE 302
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nurix Therapeutics, Inc.
CENTRAL INDEX KEY: 0001549595
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270838048
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1130
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: (415) 660-5320
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET, SUITE 205
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: Nurix, Inc.
DATE OF NAME CHANGE: 20120509
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-04-30
1
0001549595
Nurix Therapeutics, Inc.
NRIX
0001751790
Wolff Stefani
C/O NURIX THERAPEUTICS, INC.
1700 OWENS STREET, SUITE 205
SAN FRANCISCO
CA
94158
0
1
0
0
EVP and COO
0
Common Stock
2023-04-30
4
M
0
962
0.00
A
6455
D
Common Stock
2023-05-01
4
S
0
342
9.8763
D
6113
D
Restricted Stock Units
0.00
2023-04-30
4
M
0
962
0.00
D
Common Stock
962
10582
D
Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
RSUs do not expire; they either vest or are canceled prior to the vest date.
/s/ Christine Ring, as Attorney-in-Fact for Stefani Wolff
2023-05-02